Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 11/20 | 0.60 |
| ▸ | AVPR1A | P37288 | 8/20 | 0.60 |
| ▸ | AVPR2 | P30518 | 9/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2510756 | 0.90 | OXTR (0.58) | OXTRAVPR1AAVPR2KCNH2 | |
| SCHEMBL2506793 | 0.88 | AVPR1A (0.62) | OXTRAVPR1AAVPR2KCNH2 | |
| SCHEMBL2506795 | 0.88 | AVPR1A (0.62) | OXTRAVPR1AAVPR2KCNH2 | |
| SCHEMBL11962540 | 0.85 | OXTR (0.66) | OXTRAVPR1AAVPR2KCNH2 | |
| SCHEMBL12200491 | 0.85 | AVPR1A (0.65) | OXTRAVPR1AAVPR2KCNH2 | |
| SCHEMBL3331607 | 0.85 | AVPR1A (0.59) | OXTRAVPR1AAVPR2KCNH2 | |
| SCHEMBL3328372 | 0.85 | AVPR1A (0.59) | OXTRAVPR1AAVPR2KCNH2 | |
| SCHEMBL3403069 | 0.84 | OXTR (0.57) | OXTRAVPR1AAVPR2KCNH2 | |
| SCHEMBL13337802 | 0.84 | OXTR (0.57) | OXTRAVPR1AAVPR2KCNH2 | |
| SCHEMBL3405187 | 0.84 | OXTR (0.57) | OXTRAVPR1AAVPR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558467-B1 | ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| US-8461151-B2 | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2558467-A1 | ARYL - /HETEROARYL - CYCLOHEXENYL - TETRAAZABENZO [E]AZULENES AS VASOPRESSIN ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011128265-A1 | ARYL - /HETEROARYL - CYCLOHEXENYL - TETRAAZABENZO [E] AZULENES AS VASOPRESSIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| US-20110251183-A1 | ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251183-A1 | ARYL-/HETEROARYL-CYCLOHEXENYL-TETRAAZABENZO[E]AZULENES | OXTR, AVPR1B, AVPR1A | OXTR 1/4885AVPR1A 3/4885AVPR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.